The Company has more than 30 proprietary and partnered product candidates in development
Ablynx organises webcasts for analysts and investors on the occasion of financial results
Ablynx is listed on Euronext Brussels under the ticker symbol ABLX.
TAUBE HODSON STONEX PARTNERS LLP ANNOUNCE 4.35% SHAREHOLDING IN ABLYNX
22 May 2015
ABLYNX ANNOUNCES FINAL TERMS OF THE EUR 100 MILLION SENIOR UNSECURED CONVERTIBLE BONDS DUE MAY 2020
20 May 2015
ABLYNX ANNOUNCES SUCCESSFUL PLACEMENT OF EUR 100 MILLION SENIOR UNSECURED CONVERTIBLE BONDS DUE MAY 2020
Ablynx’s proprietary Nanobody platform allows for the rapid generation and large-scale production of novel biological therapeutics that have potential in a wide range of human diseases.